JP2023540270A5 - - Google Patents

Info

Publication number
JP2023540270A5
JP2023540270A5 JP2023513975A JP2023513975A JP2023540270A5 JP 2023540270 A5 JP2023540270 A5 JP 2023540270A5 JP 2023513975 A JP2023513975 A JP 2023513975A JP 2023513975 A JP2023513975 A JP 2023513975A JP 2023540270 A5 JP2023540270 A5 JP 2023540270A5
Authority
JP
Japan
Application number
JP2023513975A
Other languages
Japanese (ja)
Other versions
JP7846091B2 (ja
JPWO2022047260A5 (https=
JP2023540270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048101 external-priority patent/WO2022047260A1/en
Publication of JP2023540270A publication Critical patent/JP2023540270A/ja
Publication of JP2023540270A5 publication Critical patent/JP2023540270A5/ja
Publication of JPWO2022047260A5 publication Critical patent/JPWO2022047260A5/ja
Application granted granted Critical
Publication of JP7846091B2 publication Critical patent/JP7846091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513975A 2020-08-28 2021-08-27 複素環式化合物およびその使用 Active JP7846091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072056P 2020-08-28 2020-08-28
US63/072,056 2020-08-28
PCT/US2021/048101 WO2022047260A1 (en) 2020-08-28 2021-08-27 Heterocyclic compounds and uses thereof

Publications (4)

Publication Number Publication Date
JP2023540270A JP2023540270A (ja) 2023-09-22
JP2023540270A5 true JP2023540270A5 (https=) 2024-09-04
JPWO2022047260A5 JPWO2022047260A5 (https=) 2024-09-04
JP7846091B2 JP7846091B2 (ja) 2026-04-14

Family

ID=80353317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513975A Active JP7846091B2 (ja) 2020-08-28 2021-08-27 複素環式化合物およびその使用

Country Status (7)

Country Link
US (2) US12365676B2 (https=)
EP (1) EP4203952A4 (https=)
JP (1) JP7846091B2 (https=)
CN (1) CN116368130A (https=)
AU (1) AU2021331492A1 (https=)
CA (1) CA3191279A1 (https=)
WO (1) WO2022047260A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
CN116368130A (zh) 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
BR112023015976A2 (pt) * 2021-02-09 2023-12-12 Medshine Discovery Inc Compostos de anel aromático de pirimidina
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
JP2024517695A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
JP2024517693A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 2-アミノベンゾチアゾール化合物及びその使用方法
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物,其制法与医药上的用途
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
JP2024520791A (ja) * 2021-06-10 2024-05-24 レデックス・ファーマ・パブリック・リミテッド・カンパニー 化合物
EP4373822A2 (en) 2021-07-23 2024-05-29 Theras Inc. Compositions and methods for inhibition of ras
US20240409558A1 (en) * 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4405337A4 (en) * 2021-11-30 2025-11-26 Beta Pharma Inc Fused pyrimidine derivatives as kras oncoprotein inhibitors
IL314486A (en) * 2022-02-03 2024-09-01 Mirati Therapeutics Inc Quinazoline compounds inhibit PAN-KRAS
AU2023218370B2 (en) 2022-02-09 2024-11-28 Quanta Therapeutics, Inc. Kras modulators and uses thereof
AU2023222076A1 (en) * 2022-02-16 2024-08-15 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
EP4479398A1 (en) * 2022-02-16 2024-12-25 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
KR20240163107A (ko) 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
JP7676677B2 (ja) * 2022-03-25 2025-05-14 イーライ リリー アンド カンパニー Kras阻害剤
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑
AU2023264608A1 (en) * 2022-05-04 2024-11-07 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
IL317601A (en) 2022-05-25 2025-02-01 Quanta Therapeutics Inc Pyrimidine-based modulators and their uses
JP2025524597A (ja) * 2022-07-07 2025-07-30 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環式化合物、その組成物、及びそれによる処置方法
CN119768409A (zh) * 2022-08-25 2025-04-04 北京加科思新药研发有限公司 K-Ras突变蛋白抑制剂
TW202416976A (zh) * 2022-09-16 2024-05-01 大陸商南京明德新藥研發有限公司 含六氫螺環[環丙烷—1,2'—吡咯𠯤]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
EP4688792A1 (en) * 2023-03-31 2026-02-11 Eli Lilly and Company Kras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (https=) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
WO2004054977A1 (en) 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
EA201000316A1 (ru) * 2007-09-12 2010-10-29 ВАЙЕТ ЭлЭлСи Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
CA2834164A1 (en) * 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2014331794C1 (en) 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
JP2018513853A (ja) * 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
AU2018271990A1 (en) * 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202033518A (zh) 2018-10-15 2020-09-16 美商美國禮來大藥廠 Kras g12c 抑制劑
PT3735299T (pt) 2018-11-09 2024-11-25 Hoffmann La Roche Compostos de anéis fundidos
AU2019388998A1 (en) 2018-11-29 2021-06-03 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020238791A1 (zh) 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN112300153B (zh) 2019-07-26 2023-06-13 博瑞生物医药(苏州)股份有限公司 一种杂环化合物、药物组合物和用途
TWI752580B (zh) 2019-08-07 2022-01-11 大陸商北京加科思新藥研發有限公司 Kras突變蛋白抑制劑
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
ES2929700T3 (es) 2019-12-11 2022-12-01 Lilly Co Eli Inhibidores de KRas g12c
CN116194456B (zh) 2020-04-30 2025-08-29 上海科州药物股份有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
CN116368130A (zh) 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
CN114380827A (zh) 2020-10-22 2022-04-22 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
US20240059710A1 (en) 2020-11-20 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. KRAS G12D Inhibitors
US20240109893A1 (en) 2020-12-22 2024-04-04 Shanghai Kechow Pharma, Inc. Preparation and application method of heterocyclic compounds as kras inhibitor
CN113999226B (zh) 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
US20240140957A1 (en) 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022170999A1 (zh) 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4,3-d]嘧啶类化合物
WO2022173870A1 (en) 2021-02-09 2022-08-18 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
BR112023015976A2 (pt) 2021-02-09 2023-12-12 Medshine Discovery Inc Compostos de anel aromático de pirimidina
AU2022224511A1 (en) 2021-02-16 2023-08-10 Lawrence Livermore National Security, Llc Compositions and methods for inhibition of ras
WO2022184178A1 (en) 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022221739A1 (en) 2021-04-16 2022-10-20 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12d mutant
CN115490709A (zh) 2021-04-30 2022-12-20 四川海思科制药有限公司 一种krasg12d抑制剂及其在医药上的应用
WO2022247760A1 (zh) 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
JP2024520791A (ja) 2021-06-10 2024-05-24 レデックス・ファーマ・パブリック・リミテッド・カンパニー 化合物
WO2022266015A1 (en) 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
CN115611923A (zh) 2021-07-12 2023-01-17 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4373822A2 (en) 2021-07-23 2024-05-29 Theras Inc. Compositions and methods for inhibition of ras
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
TW202328124A (zh) 2021-08-18 2023-07-16 大陸商北京加科思新藥研發有限公司 1,4-氧雜氮雜環庚烷衍生物及其用途

Similar Documents

Publication Publication Date Title
JP2023540270A5 (https=)
JP2023531269A5 (https=)
BR102021009475A2 (https=)
CN306141016S (https=)
CN306032697S (https=)
CN305536198S (https=)
CN305536127S (https=)
CN306026170S (https=)
CN305535147S (https=)
CN305535083S (https=)
CN305534640S (https=)
CN305534125S (https=)
CN305533833S (https=)
CN305533698S (https=)
CN305533677S (https=)
CN305532616S (https=)
CN305532469S (https=)
CN305531240S (https=)
CN306139259S (https=)
CN306137298S (https=)
CN305530214S (https=)
CN306135963S (https=)
CN305530051S (https=)
CN305529817S (https=)
CN305528755S (https=)